Singular Genomics Systems (OMIC) Set to Announce Earnings on Tuesday

Singular Genomics Systems (NASDAQ:OMIC) is set to announce its earnings results after the market closes on Tuesday, August 13th. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Singular Genomics Systems (NASDAQ:OMIC) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($10.20) earnings per share for the quarter. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.50 million. Singular Genomics Systems had a negative return on equity of 51.10% and a negative net margin of 3,863.90%.

Singular Genomics Systems Stock Down 2.8 %

Shares of OMIC stock traded down $0.20 during trading on Tuesday, reaching $7.05. The company’s stock had a trading volume of 6,874 shares, compared to its average volume of 4,715. The company has a market cap of $17.39 million, a price-to-earnings ratio of -0.18 and a beta of 1.35. Singular Genomics Systems has a one year low of $6.78 and a one year high of $24.00. The business has a fifty day moving average price of $9.11 and a 200-day moving average price of $12.49. The company has a quick ratio of 9.54, a current ratio of 10.35 and a debt-to-equity ratio of 0.05.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group decreased their price objective on Singular Genomics Systems from $22.50 to $6.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.